



<b>Title</b>	<b>Oblongifolin M, an active compound isolated from a Chinese Medical herb <i>Garcinia oblongifolia</i>, potentially inhibits Enterovirus 71 reproduction through downregulation of ERp57</b>
<b>Author(s)</b>	<b>Wang, M; Dong, Q; Wang, H; He, Y; Chen, Y; Zhang, H; Wu, R; Chen, X; Zhou, B; He, J; Kung, HF; Huang, C; Wei, Y; Huang, J; Xu, H; He, ML</b>
<b>Citation</b>	<b>Oncotarget, 2016, v. 7 n. 8, p. 8797-8808</b>
<b>Issued Date</b>	<b>2016</b>
<b>URL</b>	<b><a href="http://hdl.handle.net/10722/248313">http://hdl.handle.net/10722/248313</a></b>
<b>Rights</b>	<b>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.</b>

# Oblongifolin M, an active compound isolated from a Chinese medical herb *Garcinia oblongifolia*, potently inhibits enterovirus 71 reproduction through downregulation of ERp57

Mengjie Wang<sup>1,2,\*</sup>, Qi Dong<sup>2,3,9,\*</sup>, Hua Wang<sup>3</sup>, Yaqing He<sup>4</sup>, Ying Chen<sup>9</sup>, Hong Zhang<sup>1</sup>, Rong Wu<sup>1</sup>, Xinchun Chen<sup>5</sup>, Boping Zhou<sup>5</sup>, Jason He<sup>8</sup>, Hsiang-Fu Kung<sup>2,3</sup>, Canhua Huang<sup>6</sup>, Yuquan Wei<sup>6</sup>, Jian-dong Huang<sup>7</sup>, Hongxi Xu<sup>1</sup>, Ming-Liang He<sup>9</sup>

<sup>1</sup>School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, China

<sup>2</sup>Shenzhen Research Institute, The Chinese University of Hong Kong, Shenzhen, China

<sup>3</sup>Stanley Ho Center for Emerging Infectious Diseases, The Chinese University of Hong Kong, Hong Kong, China

<sup>4</sup>Shenzhen Center for Disease Control and Prevention (Shenzhen CDC), Shenzhen, China

<sup>5</sup>Institute of Infectious Diseases, The 3rd Peoples' Hospital of Shenzhen, Shenzhen, China

<sup>6</sup>State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China

<sup>7</sup>School of Biomedical Sciences, The University of Hong Kong, Hong Kong, China

<sup>8</sup>College of Letter and Sciences, University of California at Berkeley, Berkeley, CA, USA

<sup>9</sup>Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, China

\*These authors have contributed equally to this work

**Correspondence to:** Ming-Liang He, **e-mail:** mlhe7788@gmail.com  
Hongxi Xu, **e-mail:** xuhongxi88@gmail.com

**Keywords:** enterovirus 71, Oblongifolin M, ERp57, antiviral

**Received:** October 09, 2015

**Accepted:** January 19, 2016

**Published:** February 01, 2016

## ABSTRACT

There is no effective drug to treat EV71 infection yet. Traditional Chinese herbs are great resources for novel antiviral compounds. Here we showed that *Oblongifolin M* (OM), an active compound isolated from *Garcinia oblongifolia*, potently inhibited EV71 infection in a dose dependent manner. To identify its potential effectors in the host cells, we successfully identified 18 proteins from 52 differentially expressed spots by comparative proteomics studies. Further studies showed that knockdown of ERp57 inhibited viral replication through downregulating viral IRES (internal ribosome entry site) activities, whereas ectopic expression of ERp57 increased IRES activity and partly rescued the inhibitory effects of OM on viral replication. We demonstrated that OM is an effective antiviral agent; and that ERp57 is one of its cellular effectors against EV71 infection.

## INTRODUCTION

Enterovirus 71 (EV71), a member of the *Picornaviridae* family, is a non-enveloped single-stranded RNA virus. It is the major causative agent of repeated outbreaks of hand, foot and mouth disease (HFMD) [1, 2]. In severe cases, especially those among in infants and children, EV71 infection causes severe neurological complications such as aseptic meningitis, brain stem encephalitis, pulmonary edema, poliomyelitis-like paralysis and eventual death. In the last decade, the continuous outbreaks of EV71 in Asia-Pacific region have caused considerable deaths [3]. More than 7 million

HFMD cases were reported in China between 2008 and 2012, of which 2457 were fatal [4, 5]. No effective antiviral drug is currently used for treating EV71 infection [6]; therefore, there is an urgent need for effective agent against EV71 infection.

Chinese Medical herbs are a great reservoir of active compounds against microbial infections [7–14]. Plants generate a great deal of compounds to eliminate or limit microbe invasions. The family *Guttiferae* contains more than 450 species distributed over regions mostly in Asia, southern Africa and Western Polynesia. Many bioactive compounds, such as prenylated xanthenes, benzophenones, biflavonoids, and polycyclic polyprenylated

acylphloroglucinols, have been isolated from different family members [15–23]. They exhibit various biological activities including antibacterial, antifungal, antioxidant, anti-inflammatory and anticancer effects [15–23], despite the underlining mechanisms being poorly understood.


With the growing number of natural antiviral compounds identified, a promising option would be to find new compounds from medical herbs to combat EV71 infection [24–26]. Instructed by bioactivity-guided isolation, a new isoprenyl benzophenone derivative *Oblongifolin M* (compound M from *Oblongifolia*, OM), has been isolated from medical herb *Garcinia oblongifolia* [27]. In this study, we investigated its antiviral activity against EV71 infection and the underlying mechanisms through comparable proteomics studies.

## RESULTS

### Protection of cytopathic effects (CPE) caused by EV71 infection

The antiviral effect of OM was tested in Rhabdomyosarcoma (RD) cells by CPE assays. As shown in Figure 1A, the RD cells without viral infection were flat with spindle-like shapes and attached well on the surface

of culture dishes. When cells were infected with EV71 at a multiple of infection (MOI) of 1, many cells showed CPE. They became round, detached from the surface of culture dishes and floated away 12 hours post-infection (p.i.) (Figure 1B). When the cells were pretreated with 15  $\mu$ M of OM 4 hours prior to EV71 infection, most cells were healthy with only a few exhibiting CPE (Figure 1C), an indication that the infected cells were significantly protected from CPE. Surprisingly, almost all EV71-infected cells were healthy when pretreated with 30  $\mu$ M of OM (Figure 1D). Similar results were also obtained from HEK 293 cells and Hela cells (data not shown). The reduction of EV71-induced CPE by 50% ( $IC_{50}$ ) was determined by using GraphPad Prism5. As shown in Table 1, the  $IC_{50}$  of OM was  $2.38 \pm 0.79$   $\mu$ M. Cell viability was employed to determine the toxicity of OM in RD cells by MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide) assays after treating RD cells with OM for 24h. Compared with untreated cells, cell viability was not obviously affected by OM at a concentration of 50  $\mu$ M. The  $CC_{50}$  (concentration of OM required for 50% cell kill) of the uninfected cells was  $83.87 \pm 1.12$   $\mu$ M. The selectivity of OM on RD cells was 35.24 (Table 1), indicating OM's potential to be an effective antiviral agent against EV71 infection.



**Figure 1: The inhibitory effects of OM against EV71 infection OM protected cytototoxic effects (CPE) from EV71 infection in RD cells** **A.** to **D.** RD cells were pretreated without (**A**, **B**) or with OM (**C**, **D**) for 4 hours before EV71 infection at a MOI of 1. Photos were taken 12 hours post-infection (p.i.). **E.** OM inhibited EV71 reproduction. The virions in the culture supernatant were harvested 12 hours p.i. and the viral titer was determined by TCID<sub>50</sub> assays. **F.** OM inhibited EV71 replication. 12 hours p.i., the intracellular RNA was isolated, and viral genomic RNA (primers targeting VP1 gene) and cellular mRNA of GAPDH genes were quantitated by qRT-PCR. The viral genomic RNA level was normalized with the copy number of mRNA of GAPDH. The mean value of VP1/GAPDH ratio was set as 1 in control. **G.** The viral VP1 protein was decreased by OM in a dose dependent manner. The cells were harvested 12 hours p.i. at MOI of 1, and cell lysate was applied for Western blot assays.



**Table 1: Cytotoxic, antiviral activity and selectivity index of OM against EV71**

Compound	Cytotoxicity	Antiviral activity <sup>a</sup>	Selectivity Index
OM	CC <sub>50</sub> (μM)	IC <sub>50</sub> (μM)	SI (CC <sub>50</sub> /IC <sub>50</sub> )
	83.87±1.12 <sup>b</sup>	2.38±0.79 <sup>b</sup>	35.24

a. RD cells were infected with EV71 at a MOI of 0.01 after treatment with serial dilution of OM for 4 h.

b. Values obtained from nonlinear regression analysis using GraphPad Prism5.

Values represent the mean ± SD of three independent experiments.


**Inhibition of EV71 propagation**

To further determine OM’s antiviral potency, we titrated the viral titers in the culture media. As shown in Figure 1E, the mean value of viral titers was  $5.6 \times 10^6$  pfu/ml in the control group. After treatment of the cells with 15 μM of OM, the viral titers significantly decreased to  $3.42 \times 10^6 \pm 6.4 \times 10^5$  pfu/ml. When the concentration of OM was increased to 30 μM, surprisingly, the viral titers dramatically dropped by over 90% to  $2.5 \times 10^5 \pm 1.1 \times 10^5$  pfu/ml. The antiviral effects were further validated by measuring the intracellular viral genomic RNA copies and viral protein levels. Twelve hours after infection, the copy number of viral genomic RNA decreased by 23%, 65%, 84% and 95% after cells were treated with OM at concentrations of 15, 20, 25, and 30 μM, respectively (Figure 1F). Consistently, the levels of intracellular VP1 protein were significantly inhibited by OM in a dose dependent manner (Figure 1G).

**The effects of OM on protein profiles**

To investigate the potential antiviral mechanisms of OM against EV71 infection, we employed comparable proteomics studies. Proteins from RD cells treated with

DMSO (control) or 30 μM of OM were extracted and resolved by 2-DE analysis 48 hours post-treatment. Figure 2 shows a representative pair of silver-stained 2-DE maps between two samples from three pairs of gels (Figure 2A and 2B). After comparison, 52 spots showed significant (with over 2-fold,  $p < 0.05$ ) difference. The individual protein spot was extracted and digested for MALD-TOF MS and MS/MS analysis. Typical images of five paired spots were cropped and enlarged as shown in Figure 2C. We successfully identified 18 proteins with significant differential expression. Among them, eight proteins were markedly up-regulated whereas ten were down-regulated in the OM-treated RD cells as compared to the control group. The characteristics of proteins (including name, abbreviation, NCBI accession number, theoretical molecular mass, pI, peptide count, protein score (confidence interval in percent), number of unmatched masses, sequence coverage, fold change, and functions) are listed in Table 2. Functionally, they can be categorized into six categories: structural molecular activity (17%), metabolism (39%), cytoskeleton and transport proteins (11%), gene transcription associated proteins (6%), heat shock proteins and chaperones (17%), and cell proliferation, metastasis, and signal transduction proteins (11%).



**Figure 2: Protein profile differences between Control and OM-treated RD cells.** A. and B. representative silver-stained 2-DE maps of proteins from DMSO and 30 μM of OM (resolved in DMSO) treated RD cells. Fifty two differential expressed spots were picked up for MALDI-TOF-MS and MS/MS analysis. The spots of eighteen differently expressed proteins identified were marked. C. The enlarged sections of the 2-DE map. Spot 4, RCN-3; spot 5, RCN-1; spot 6, calumenin; and spot 17, ERp57.

**Table 2: Differentially expressed proteins identified by 2-DE/MS analysis in RD cells treated without/with OM (At a 2-fold difference cutoff in intensity, xx spots were selected for further MALD-TOF-MS/MS analysis, 18 proteins were finally identified)**

Spots No. <sup>a</sup>	Protein name	Abbreviation	NCBI accession no.	Theoretical molecular mass(Da)	PI	Protein core (CI)	Masses matched/ searched	Sequence-coverage (%)	'-Fold change <sup>b</sup>
<b>Structural molecule activity</b>									
1	Rho-associated protein kinase 2	ROCK2	O75116	161939	5.75	69	9/13	5	11.7↓
24	Prelamin-A/C	LMNA	P02545	74380	6.57	97	15/36	22	4.1↓
26	Annexin A7	ANXA7	P20073	52991	5.52	71	8/21	15	3.7↑
<b>Metabolism</b>									
4	Reticulocalbin-3	RCN3	Q96D15	37470	4.74	94	8/27	32	18.2↓
5	Reticulocalbin-1	RCN1	Q15293	38866	4.86	115	12/34	34	15.3↓
6	Calumenin	CALU	O43852	37198	4.47	80	9/30	26	4.3↓
7	Proteasome subunit alpha type-3	PSMA3	P25788	28643	5.19	60	6/26	20	3.8↑
15	N(G),N(G)-dimethylarginine dimethylamino-hydrolase 2	DDAH2	O95865	29911	5.66	59	6/28	18	3.6↑
21	Mitochondrial inner membrane protein	IMMT	Q16891	84025	6.08	117	14/28	16	3.3↓
37	26S protease regulatory subunit 10B	PSMC6	P62333	44430	7.1	58	6/14	13	3.3↑
<b>Cytoskeleton and transport proteins</b>									
8	Actin, cytoplasmic 1	ACTB	P60709	42052	5.29	111	9/29	26	3.8↑
22	Vinculin	VCL	P18206	124292	5.5	96	14/27	11	3.0↑
<b>Gene transcription</b>									
39	Far upstream element-binding protein 1	FUBP1	Q96AE4	67690	7.18	110	11/21	17	3.1↑
<b>Heat shock proteins and chaperones</b>									
17	Protein disulfide-isomerase A3	ERp57	P30101	57146	5.98	76	11/31	17	13↓
18	T-complex protein 1 subunit alpha	TCP1	P17987	60819	5.8	77	9/24	16	3.4↓
27	T-complex protein 1 subunit beta	CCT2	P78371	57794	6.01	121	13/29	22	3.9↓
<b>Cell proliferation, metastasis, and signal transduction</b>									
33	Septin-11	SEPT11	Q9NVA2	49652	6.36	114	12/22	22	8.5↑
34	Fascin	FSCN1	Q16658	55123	6.84	103	10/24	18	10.8↓

<sup>a</sup> Spot numbers are shown in Figure 2.

<sup>b</sup> The spot intensities were quantified using PDQuest software (Bio-Rad). The average -fold change of spot intensity for each protein was calculated from three independent experiments (DMSO-treated RD versus OM-treated RD). ↑, increase; ↓, decrease.

## Validation of differentially expressed protein by western blot assay

We carried out Western blot assays to confirm the differentially expressed protein levels after we treated the RD cells with OM for 48 hours. Among five selected candidate proteins, four displayed similar expression patterns as shown in the 2-DE assays. The protein levels of ERp57, RCN-1, RCN-3, and CALU significantly decreased after OM treatment (Figure 3A).

ERp57 drew our particular attention because it is crucial for the entry of SV40 and murine rotavirus [28, 29]. To further observe the correlation between the expression levels of ERp57 and EV71 viral proteins, RD cells were treated with or without 30  $\mu$ M of OM for 4 hours, and then infected with EV71 (MOI 1). As shown in Figure 3B, OM not only suppressed ERp57 expression, but also significantly decreased viral VP1 and VP2 levels. These results indicated that ERp57 might involve the life cycle of EV71.


## Suppression of EV71 by knockdown of ERp57

We tested the effects of ERp57 knockdown on EV71 infections. As shown in Figure 4A, both si-ERp57-1 and ERp57-2 effectively reduced the mRNA level of ERp57. As si-ERp57-1 was more effective on knocking down ERp57, si-ERp57-1 was chosen for further experiments in our study. Consistent with the reduction of mRNA level, ERp57 protein level was also significantly decreased by si-ERp57-1 (Figure

4B). We further examined if knockdown of ERp57 would affect virus entry. RD cells were first transfected with either scrambled or si-ERp57-1 for 48 hours, and then infected with EV71 at MOI of 20 for 1 hour on ice. The infected cells were washed with PBS for three times to remove potential free viruses that had not entered the cells. We employed qRT-PCR to measure the intracellular viral RNA levels. Our data showed that the entry of EV71 had not been affected by ERp57 knockdown (Figure 4C). To further investigate if ERp57 knockdown would affect EV71 replication or reproduction, we first measured the intracellular viral RNA levels at different time points. We showed that ERp57 knockdown significantly decreased the intracellular viral RNA levels at 3 and 5 hours p.i. (Figure 4D), and markedly reduced the secreted virions in the culture media collected at 5 and 7 hours p.i. (Figure 4E). These results indicate that ERp57 was involved in the early phase of viral life cycle.

## Inhibition of IRES activity by OM and ERp57

Our previous study showed that active replication of EV71 occurs just after uncoating (3 to 6 hours p.i.) [30]. After uncoating, the first and key event is viral protein translation driven by IRES [31]. Therefore, we hypothesized that OM may inhibit EV71 infection by down-regulation of IRES activity through ERp57. To test this hypothesis, we generated two constructs to express reporters *Renilla* luciferase (RLuc) and *Firefly* luciferase (FLuc). As shown in Figure 5A, two continuous stop codes (TGA TGA) were inserted between RLuc and FLuc




**Figure 3: The suppression of ERp57 expression by OM.** A. RD cells were treated with OM at 30  $\mu$ M for 48 hours, and cell lysates were harvested and applied for Western blot assays. As shown, ERp57, RCN-1, RCN-2 and Calumenin were markedly down-regulated by OM treatment. B. Cells were pretreated with 30  $\mu$ M of OM for 4 hours, and then infected with EV71 at MOI of 1 for 12 hours. As shown, OM suppressed the expression of ERp57, and viral proteins VP1 and VP2. The relative density value of each band to GAPDH was set as 1 in the control group.

genes in pRF plasmid; while the IRES sequence of EV71 was inserted between RLuc and FLuc genes in pIRES plasmids. In both constructs, the CMV promoter drives RLuc expression. FLuc translation is stopped when mRNA is transcribed from pRF, whereas the translation would be successful from that of pIRES. Hence, the IRES activity can be measured and expressed by the ratio of FLuc to RLuc activities.

We showed that OM did not affect the ratio of FLuc/RLuc when cells were transfected with pRF plasmid; however, the ratio of FLuc/RLuc decreased after cells were transfected with pIRES and treated with OM. The inhibition of IRES activity was in a dose-dependent manner (Figure 5B). As expected, when ERp57 was knocked down, the IRES activity of EV71 markedly decreased (Figure 5C), correlating with the inhibitory effects of OM.


## Restoration of OM-suppressed IRES activity by ectopic expression of ERp57

We constructed an expression plasmid to express human ERp57 in HEK 293 cells. As shown in Figure 6A, the ectopic expression of ERp57 significantly stimulated the IRES activity of EV71. Furthermore, we examined if ectopic expression of ERp57 would restore the viral replication that had been inhibited by OM. ERp57 was ectopically expressed in RD cells and pretreated with OM at 30  $\mu$ M for 4 hours. The cells were then infected with EV71 at MOI 1. We showed that the viral RNA level decreased to 25% that of the control 5 hours p.i., whereas the viral RNA level was restored to that 53% of the control upon overexpression of ERp57. Our results demonstrated that ERp57 partly restored the IRES activity suppressed by OM.




**Figure 4: Inhibition of EV71 infection by Knockdown of ERp57 at early stage.** **A.** Specific siRNAs targeting ERp57 were transfected into RD cells, and the effect of knockdown was determined by qRT-PCR 48 hours post-transfection. **B.** The ERp57 protein level detected by si-ERp57-1 knockdown. **C.** Knockdown of ERp57 did not affect EV71 entry. Forty eight hours post-transfection with siRNAs, cells were infected with EV71 at MOI of 1 for 1 hour (time point was set as 0 hour), and cells were washed with PBS for three times. The intracellular viral RNA level was determined by qRT-PCR. The mean value of VP1/GAPDH ratio was set as 1 in control. **D.** and **E.** The intracellular (D) and extracellular (E) viral RNA levels upon ERp57 knockdown at different time points. The total RNA was isolated from infected cells and corresponding media at different time points, and quantified by quantitative RT-PCR. At time point 0 hour, the intracellular viral RNA level (virions just entered the cells) were quantitated by qRT-PCR \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$ .





**Figure 5: Inhibition of EV71 IRES activity by OM or knockdown of ERp57.** A. Schematic diagram of plasmids pIRES and pRF for measuring IRES activity. B. OM inhibited IRES activity in a dose dependent manner. Cells were transfected with pIRES or pRF for 24 hours, and then treated without or with OM for 12 hour followed by luciferase assays. C. Knockdown of ERp57 reduced IRES activity. Cells were transfected with scramble siRNA or si-ERp57-1. Twenty four hours post-transfection, the cells were then transfected with pIRES or pRF for another 24 hours and applied for luciferase assays. The ratio of FLuc to RLuc activity was set as 1 when cells were transfected with pRL reporter plasmid in the control group (without OM treatment or transfected with scrambled siRNA). \*,  $p < 0.05$ ; \*\*\*,  $p < 0.001$ .



**Figure 6: Ectopic expression of ERp57 enhanced IRES activity.** A. Ectopic expression ERp57 increased the reporter expression driven by IRES; B. Ectopic expression of ERp57 partly rescued OM's inhibitory effect on IRES. \*\*,  $p < 0.01$ .



## DISCUSSION

There is no effective drug to treat EV71 infection [31–33]. In this paper, we showed that an effective compound OM isolated from *Garcinia oblongifolia* displayed potent anti-EV71 activity through downregulation of ERp57, an important host factor in the early phase of EV71 life cycle.

Host proteins are ideal targets for antiviral drug development because targeting host proteins would avoid or delay the occurrence of drug resistance due to fast mutagenesis of viruses. ERp57, a chaperon protein involved in catalyzing disulfide bond exchange for correct protein folding in ER stress, has been shown a crucial role in the entry of DNA virus SV40 [28]. Besides virus entry, it is possible that ERp57 may exhibit other functions in the life cycle of other viruses. As an RNA virus, EV71 has a life cycle that is completely different from that of SV40. An important question is whether ERp57 exhibits a similar function in the life cycle of EV71. To address this question, we first investigated if the viral entry of EV71 would be affected by knockdown of ERp57. To our surprise, the depletion of ERp57 did not affect virus entry into the host cells (Figure 4C). Interestingly, we found that the virus replication was significantly suppressed at 3 to 5 hours p.i. after ERp57 knockdown in the host RD cells (Figure 4D). Accordingly, the secreted virions evidently decreased at 5 to 7 hours p.i. (Figure 4E). In our previous study, we have shown that EV71 undergoes the fast replication phase from 3 to 6 hours p.i. in RD cells, and carries out fast package from 6 to 9 hours p.i. (package phase) and secretion initiation [30]. Our results suggested that ERp57 involves mainly in the early phase of viral life cycle.

The first event of viral activity is IRES-mediated translation in generating proteins required for viral RNA replication after uncoating of virus in the host cells. We hypothesized that ERp57 may affect viral translation through regulating viral IRES activities. Our results showed that knockdown of ERp57 significantly reduced the viral IRES activities (Figure 5B). Intriguingly, OM also suppressed the IRES activity in a dose dependent manner (Figure 5C), demonstrating a correlation between drug effects and ERp57 functions. To further validate our findings, we conducted gain-of-function studies. ERp57 was ectopically expressed in host cells to test its effects on IRES activity. As expected, results from this study exhibited an increase of IRES activity by ectopic ERp57 expression (Figure 6A). This suggests that OM may affect ERp57 functions in an indirect or direct manner. We have noted that ectopic expression of ERp57 partly rescued the inhibition of early replication of EV71 (Figure 6B), indicating that in addition to ERp57, there must be other host factors contributing to the inhibitory effects of OM on EV71 reproduction. As shown in Table II, 10 proteins were down-regulated and 8 proteins were

upregulated by OM. Whether these proteins contribute to the viral inhibition of OM should be investigated in future studies. Although several other compounds isolated from *Garcinia oblongifolia* (e.g., Oblongifolia L or P) share similar structure to OM, its antiviral effects against EV71 was much weaker (data not shown). Further investigating the underlying mechanism may help us to develop OM derivatives with more potent anti-EV71 activity.

In summary, we showed that OM, an active compound isolated from a traditional Chinese herb, potently inhibited EV71 infection. By employing comparative proteomics studies, we identified that ERp57 was an effector of OM. Knockdown of ERp57 inhibited viral replication through downregulating viral IRES activities, whereas ectopic expression of ERp57 increased IRES activity and partly rescued the inhibition of viral replication by OM. Our results demonstrated that OM inhibited the early replication of EV71 partly through downregulating ERp57. OM could potentially be further developed into a therapeutic drug for treating EV71 infections, and ERp57 may serve as a target for developing host-based antiviral drugs against EV71 infection.

## MATERIALS AND METHODS

### Chemicals and antibodies

Chemicals were purchased from Sigma (St. Louis, MO, USA). Oblongifolin M (OM) was previously identified and isolated with purity over 98% [27]. Commercially available antibodies were purchased from different companies. Antibody against VP1 was from Abnova (Cat. No. PAB7630-B01P), VP2 specific antibody was from Millipore (Cat. No. MAB979), rabbit polyclonal anti-RCN1 (Cat. No. ab129796), anti-RCN3 (Cat. No. 134228), anti-CALU (Cat. No. ab118308), and anti-ROCK2 (Cat. No. ab66320) were from Abcam, anti-ERp57 (Cat. No. H-220) and anti-GAPDH (Cat. No. sc-32233) specific antibody and all the corresponding secondary antibodies were purchased from Santa Cruz Biotechnology.

### Cell culture, virus propagation and compound

Rhabdomyosarcoma cells (RD, ATCC accession no. CCL-136) were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% (v/v) fetal bovine serum (FBS, HyClone) with 100 U/ml penicillin and 100 µg/ml streptomycin, at a humidified condition of 5% CO<sub>2</sub> at 37 °C. EV71 (SHZH98 strain; GenBank accession number AF302996.1) [30, 44, 45] was propagated on 90% confluent monolayer cells in DMEM with 2% FBS. When about 80% of the cells exhibited CPE, culture fluid was collected, centrifuged, filtrated and stored in -80°C until use. The viral titer was determined by the end-point dilution assay of median tissue culture infective dose (TCID<sub>50</sub>).

## CPE assay

Antiviral activity of OM was evaluated by CPE assays. Approximately 20,000 RD cells per well were laid in 96-well plate for 24 hours at 37°C to reach monolayer, then treated with OM at different concentrations and infected by EV71 at MOI of 0.01 or 1 (Supplementary Table S1). CPE was monitored from time to time under a phase-contrast microscope and recorded by a CCD camera. The concentration required for the tested compound to reduce the EV71-induced CPE by 50% ( $IC_{50}$ ) was determined by using the Forecast function of Microsoft Excel for all experiments. Data were shown as mean values with standard deviations from three independent assays. Selectivity index (SI) is calculated by the ratio of  $CC_{50}$  to  $IC_{50}$ .

## Cytotoxicity test

Cytotoxicity of OM was evaluated by cell viability assays. RD cells (about 20,000 cells) were set in each well of a 96-well plate overnight to reach monolayer and exposed to serial dilution of OM for 24 hours. Cell viability was measured by the MTT method as described previously [46, 47]. The  $CC_{50}$  was calculated.

## Western blot

Cells were lysed in radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% SDS, 1×Roche protease inhibitor cocktail) with occasional vortex. The cell lysates were then centrifuged to remove debris at 14,000 rpm for 20 min at 4°C. The concentration of proteins in the lysates was determined by Bradford assay (Bio-Rad). Equal amounts of total protein for each sample was loaded and separated by 8% to 12% SDS-PAGE and then transferred onto polyvinylidene difluoride (PVDF) membranes (Amersham Biosciences). Membranes were blocked with 5% skim milk in TBST (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% Tween 20) for 1 h and incubated with specific antibodies. GAPDH was served as the loading control. Target proteins were detected with corresponding secondary antibodies (Santa Cruz Biotechnology), visualized with a chemiluminescence detection system (Amersham Biosciences). Each immunoblot assay was carried out at least three times as previously reported [44].

## Real-time RT-PCR

The total cellular RNA was extracted using TRIzol reagent (Invitrogen) according to the manufacturer's instructions. The virion RNA in the culture media was isolated using a viral RNA isolation kit (Qiagen). RNA was then reverse transcribed into cDNA using a reverse transcription system (Promega). Quantitative reverse transcription-PCR (qRT-PCR) was carried out by using an ABI 7500 Real-Time PCR system with SYBR Premix

Ex Taq (Takara). The PCR was set up under the following thermal cycling conditions: 95°C for 30 s, followed by 40 cycles of 95°C for 5 s and 60°C for 34 s. The threshold cycle (CT) value was normalized to that of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) [47, 48]. The qRT-PCR was performed by using the following primer pairs: GAPDH, 5'-GATTCCACCCATGGCAAATTCCA-3' (forward) and 5'-TGGTGATGGGATTTCATTGATGA-3' (reverse); EV71, 5'-GCAGCCCCAAAAGAACTTCAC-3' and 5'-ATTTCAGCAGCTTGGAGTGC-3'; for ERP57, 5'-GTGCTAGAACTCACGGACGA-3' and 5'-GCTGCAGCTTCATACTCAGG-3'. All samples were run in triplicates, and the experiment was repeated three times. The relative mRNA level of each target gene was expressed as fold change relative to the value of the corresponding control.

## Two-dimensional gel electrophoresis and image analysis

RD cells were treated with 30  $\mu$ M of OM (in DMSO) or an equal amount of DMSO for 48 hours. The cells were washed with wash buffer (10 mM Tris, 250 mM sucrose, pH 7.0) six times to remove salt ions thoroughly, lysed with lysis buffer (8 M urea, 2 M thiourea, 2% CHAPS, 1%Nonidet P-40, 2 mM tributylphosphine, 1× Roche Applied Science protease inhibitor mixture, 1× nuclease mixture, 1 mM PMSF, 2% IPG buffer), and then left on ice for 45 min with occasional vortex. The lysates were centrifuged (14,000 g for 15 min) at 4 °C, the supernatants were collected and stored at -80 °C until use. Protein concentrations were measured by Bradford assay (Bio-Rad). Isoelectric focusing was conducted with 13-cm precast IPG strips (pH 4–7, linear; GE Healthcare) by an Ettan IPGphor II IEF System (Amersham Biosciences). The IPG strips containing 150  $\mu$ g of protein samples were rehydrated for 10 h at 30 V with 250  $\mu$ l rehydration buffer (8 M urea, 2% CHAPS, 0.4% DTT, 0.5% IPG buffer, 0.002% bromphenol blue). We then focused the rehydrated strips using a stepwise voltage increment program: 500 and 1000 V for 1 h each and 8000 V afterward until 64 kV-h. After IEF, we incubated the isoelectrically focused strips in an equilibration buffer (6 M urea, 1% DTT, 2% SDS, 30% glycerol, 0.002% bromphenol blue, 50 mM Tris-HCl, pH 6.8) for 15 min with gentle agitation, then incubated the strips for another 15 min in the same buffer containing 2.5% iodoacetamide without DTT. Then we loaded the equilibrated strips onto 12.5% SDS-polyacrylamide gels, run at 15 mA/gel for 30 min and then 30 mA/gel until the dye fronts reached the bottoms of the gels. We stained the gels by modified silver staining, which was compatible with MS analysis. Gels were scanned with a calibrated GS-800 scanner (Bio-Rad), and the intensity of spots was calculated and compared by using Quantity One and PDQuest 2-D analysis software (version 8.0; Bio-Rad) as described previously [35]. A 2-fold increase/decrease (DMSO-treated

versus OM-treated RD cells) of spot intensities was set as the threshold for indicating significant changes.

### **MALDI-TOF/TOF MS and MS/MS spectrometry analysis**

Selected spots were manually cut from the gels, destained, washed and dried completely by vacuum and digested with 10 µg/ml trypsin (Promega) in 25 mM ammonium bicarbonate, pH 8.0 for 16–18 h at 37 °C. The supernatants containing tryptic peptides were collected. We mixed 2 µl of peptide solution with 0.6 µl of matrix (6 mg/ml  $\alpha$ -cyano-4-hydroxycinnamic acid in 45% ACN and 0.2% TFA) before spotting onto the MALDI plate. The samples were applied for mass spectrometric analyses by using a MALDI-TOF/TOF tandem mass spectrometer Ultraflex III proteomics analyzer (Bruker Daltonics). We obtained mass spectra from 2000 laser shots with an accelerating voltage of 20 kV with mass ranges of 700–4000 m/z in a positive ion reflectron mode and mass errors of less than 100 ppm by using the FlexControl (version 3.3.108.0, Bruker Daltonics). We obtained MS/MS spectra by collecting 3000 laser shots with a default calibration. The detected MS/MS peaks were set on a minimum S/N ratio  $\geq 3$  and cluster area S/N threshold  $\geq 15$  with smoothing, as described previously [49]. The information from combined MS and MS/MS analysis was applied for protein identification search against SwissPort database (545388 protein sequences; released on June 23, 2014) by the Mascot search engine (version 2.2.04; Matrix Science) and BioTools software (version 3.5; Bruker Daltonics). The search parameters were defined as follows: taxonomy of Homo sapiens, trypsin digest with a maximum of one missed cleavage, fixed modification of cysteine carbamidomethylation, variable modification of methionine oxidation, monoisotopic peptide mass ( $MH^+$ ), mass range unrestricted, pI of 0–14, precursor tolerance of 100 ppm, and MS/MS fragment tolerance of 0.5 Da. Before database searching, we removed the known contaminant ions from the spectra, which correspond to human keratin and trypsin autolysis peptides. The top 20 hits for each protein search were reported. The protein candidate was reported only when it met the maximum number of matched peptides and a pI value nearest to the observed value. Each isoform of a protein family, which was identified, was considered to be a distinct protein for analysis, as described previously [49].

### **siRNA synthesis and transfection**

Specific siRNA for ERp57 (siERp57-1) was purchased from QIAGEN (Cat. No. SI02654771). An in-house designed siRNA (si-ERp57-2) and nonspecific siRNA (Scrambled siRNA) were synthesized by GenePharma Co. (Shanghai). Scrambled siRNA (5' UUC UCC GAA CGU GUC ACG UTT ACG U 3'), which displays no homology to EV71 or

the human genome, was used as the negative control (NC) in this study. RD cells were transfected with siRNAs with HiPerFect transfection reagent (Qiagen) according to the manufacturer's instructions. The efficiency of knockdown was measured by qRT-PCR and Western blot assays.

### **EV71 infection, quantification of intracellular and extracellular viral genomic RNA**

RD cells were preincubated with OM for 4 hours or transfected with siRNAs for 48 hours, the cells were washed twice with phosphate buffered saline (PBS) and infected with EV71 at MOI of 1. Time was set to zero after adsorption for 1 h. The culture media were removed and cells were washed twice with PBS to remove unattached virus before adding 0.2 mL of DMEM medium containing 2% FBS to each well. To quantify the intracellular viral RNA or extracellular viral RNA in the virions, total RNA was isolated from infected cells or culture media at different time-points and further subjected to qRT-PCR assays [30].

### **Luciferase activity assay**

Cells (HEK 293) were set in 12-well dishes overnight, then transfected with 100 ng of pRF or pIRES plasmid. 24 hours post-transfection, cells were treated without or with OM at a final concentration of 15 or 30 µM for 12 hours. The cells were then harvested and cell lysates were applied for luciferase assays using a Dual Luciferase Assay System (Promega, WI) in accordance with manufacturer's instructions.

### **Statistical analysis**

Results were expressed as mean  $\pm$  standard deviation (SD). All statistical analyses were carried out with SPSS, version 14.0 software (SPSS Inc.). Two-tailed Student's t test was applied for two group comparisons. A p value  $< 0.05$  was considered statistically significant.

### **ACKNOWLEDGMENTS**

The work was partly supported by The National Basic Research Development Program (Grant No. 2013CB911302), Grants from National Science Foundation of China (81471964), Grants from The Science Technology and Innovation Committee of Shenzhen Municipality (JCYJ20130401172046448, JCYJ20120615085419420, JSGG20151030110921727), and the general research grant of Hong Kong (RGC-GRF Nos. 14105214, 464512, 11100215) to Dr. Ming-Liang HE; and by grant of The Significant New Drug Development from National Major Scientific and Technological Special Project (No. 2013ZX09103002-020) to Dr. Hong-xi Xu.



## CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

## Author contributions

HX and MLH designed the research. MD, QD, HW, YH, YC, HZ and RW conducted experiments; XC, BZ, CH, HFK, YW and JDH discussed the experiment design and carried out data assays; JH and MLH wrote the paper.

## REFERENCES

1. Chang HL, Chio CP, Su HJ, Liao CM, Lin CY, Shau WY, Chi YC, Cheng YT, Chou YL, Li CY, Chen KL and Chen KT. The association between enterovirus 71 infections and meteorological parameters in Taiwan. *PLoS One*. 2012; 7:e46845.
2. Chong P, Liu CC, Chow YH, Chou AH and Klein M. Review of enterovirus 71 vaccines. *Clin Infect Dis*. 2015; 60:797–803.
3. Li L, Yin H, An Z and Feng Z. Considerations for developing an immunization strategy with enterovirus 71 vaccine. *Vaccine*. 2015; 33:1107–1112.
4. Li YP, Liang ZL, Xia JL, Wu JY, Wang L, Song LF, Mao QY, Wen SQ, Huang RG, Hu YS, Yao X, Miao X, Wu X, Li RC, Wang JZ and Yin WD. Immunogenicity, safety, and immune persistence of a novel inactivated human enterovirus 71 vaccine: a phase II, Randomized, double-blind, placebo-controlled Trial. *J Infect Dis*. 2014; 209:46–55.
5. Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, Tan X, Wang L, Mao Q, Wu J, Hu Y, Ji T, Song L, Liang Q, Zhang B, Gao Q, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. *N Engl J Med*. 2014; 370:818–828.
6. Lu J, Yi L, Ke C, Zhang Y, Liu R, Chen J, Kung HF and He ML. The interaction between human enteroviruses and type I IFN signaling pathway. *Crit Rev Microbiol*. 2015; 41:201–207.
7. Chung YC, Hsieh FC, Lin YJ, Wu TY, Lin CW, Lin CT, Tang NY and Jinn TR. Magnesium lithospermate B and rosmarinic acid, two compounds present in *Salvia miltiorrhiza*, have potent antiviral activity against enterovirus 71 infections. *Eur J Pharmacol*. 2015; 755:127–133.
8. Ji P, Chen C, Hu Y, Zhan Z, Pan W, Li R, Li E, Ge HM and Yang G. Antiviral activity of *Paulownia tomentosa* against enterovirus 71 of hand, foot, and mouth disease. *Biol Pharm Bull*. 2015; 38:1–6.
9. Wang C, Wang P, Chen X, Wang W and Jin Y. *Saururus chinensis* (Lour.) Baill blocks enterovirus 71 infection by hijacking MEK1-ERK signaling pathway. *Antiviral Res*. 2015; 119:47–56.
10. Fu S, Sun C, Tao X and Ren Y. Anti-inflammatory effects of active constituents extracted from Chinese medicinal herbs against *Propionibacterium acnes*. *Natural product research*. 2012; 26:1746–1749.
11. Chen Y and Zhu J. Anti-HBV effect of individual traditional Chinese herbal medicine in vitro and in vivo: an analytic review. *Journal of viral hepatitis*. 2013; 20:445–452.
12. Sauter D, Schwarz S, Wang K, Zhang R, Sun B and Schwarz W. Genistein as antiviral drug against HIV ion channel. *Planta medica*. 2014; 80:682–687.
13. Schwarz S, Sauter D, Wang K, Zhang R, Sun B, Karioti A, Bilia AR, Efferth T and Schwarz W. Kaempferol derivatives as antiviral drugs against the 3a channel protein of coronavirus. *Planta medica*. 2014; 80:177–182.
14. Cheng HY, Lin LT, Huang HH, Yang CM and Lin CC. Yin Chen Hao Tang, a Chinese prescription, inhibits both herpes simplex virus type-1 and type-2 infections in vitro. *Antiviral Res*. 2008; 77:14–19.
15. Duangsrirai S, Choowongkamon K, Bessa LJ, Costa PM, Amat N and Kijjoa A. Antibacterial and EGFR-Tyrosine Kinase Inhibitory Activities of Polyhydroxylated Xanthenes from *Garcinia succifolia*. *Molecules*. 2014; 19:19923–19934.
16. Samprasit W, Opanasopit P, Sukma M and Kaomongkolgit R. Antibacterial activity of *Garcinia mangostana* extracts on oral pathogens. *Minerva stomatologica*. 2014; 63:249–257.
17. Mackeen MM, Ali AM, Lajis NH, Kawazu K, Kikuzaki H and Nakatani N. Antifungal garcinia acid esters from the fruits of *Garcinia atroviridis*. *Zeitschrift fur Naturforschung C, Journal of biosciences*. 2002; 57:291–295.
18. Suttirak W and Manurakchinakorn S. In vitro antioxidant properties of mangosteen peel extract. *Journal of food science and technology*. 2014; 51:3546–3558.
19. Fu WW, Tan HS and Xu HX. [Research progress of chemistry and anti-cancer activities of natural products from Chinese *Garcinia* plants]. *Yao xue xue bao = Acta pharmaceutica Sinica*. 2014; 49:166–174.
20. Gopalakrishnan G, Banumathi B and Suresh G. Evaluation of the antifungal activity of natural xanthenes from *Garcinia mangostana* and their synthetic derivatives. *Journal of natural products*. 1997; 60:519–524.
21. Sharma A, Joseph GS and Singh RP. Antioxidant and antiplatelet aggregation properties of bark extracts of *Garcinia pedunculata* and *Garcinia cowa*. *Journal of food science and technology*. 2014; 51:1626–1631.
22. Zhang H, Zhang DD, Lao YZ, Fu WW, Liang S, Yuan QH, Yang L and Xu HX. Cytotoxic and anti-inflammatory prenylated benzoylphloroglucinols and xanthenes from the twigs of *Garcinia esculenta*. *Journal of natural products*. 2014; 77:1700–1707.
23. Han QB, Qiao CF, Song JZ, Yang NY, Cao XW, Peng Y, Yang DJ, Chen SL and Xu HX. Cytotoxic prenylated phenolic compounds from the twig bark of *Garcinia xanthochymus*. *Chemistry & biodiversity*. 2007; 4:940–946.
24. Lin CW, Wu CF, Hsiao NW, Chang CY, Li SW, Wan L, Lin YJ and Lin WY. Aloe-emodin is an interferon-inducing agent with antiviral activity against Japanese encephalitis virus and enterovirus 71. *Int J Antimicrob Agents*. 2008; 32:355–359.



25. Lin YJ, Lai CC, Lai CH, Sue SC, Lin CW, Hung CH, Lin TH, Hsu WY, Huang SM, Hung YL, Tien N, Liu X, Chen CL and Tsai FJ. Inhibition of enterovirus 71 infections and viral IRES activity by *Fructus gardeniae* and geniposide. *European journal of medicinal chemistry*. 2013; 62:206–213.
26. Zhu QC, Wang Y, Liu YP, Zhang RQ, Li X, Su WH, Long F, Luo XD and Peng T. Inhibition of enterovirus 71 replication by chrysosplenetin and penduletin. *European journal of pharmaceutical sciences*. 2011; 44:392–398.
27. Zhang H, Tao L, Fu WW, Liang S, Yang YF, Yuan QH, Yang DJ, Lu AP and Xu HX. Prenylated benzoylphloroglucinols and xanthenes from the leaves of *Garcinia oblongifolia* with antienteroviral activity. *Journal of natural products*. 2014; 77:1037–1046.
28. Schelhaas M, Malmstrom J, Pelkmans L, Haugstetter J, Ellgaard L, Grunewald K and Helenius A. Simian Virus 40 depends on ER protein folding and quality control factors for entry into host cells. *Cell*. 2007; 131:516–529.
29. Santana AY, Guerrero CA and Acosta O. Implication of Hsc70, PDI and integrin  $\alpha$ v $\beta$ 3 involvement during entry of the murine rotavirus ECwt into small-intestinal villi of suckling mice. *Arch Virol*. 2013; 158:1323–1336.
30. Lu J, He YQ, Yi LN, Zan H, Kung HF and He ML. Viral kinetics of enterovirus 71 in human abdomiosarcoma cells. *World J Gastroenterol*, 2011; 17:4135–4142.
31. Yi L, Lu J, Kung HF and He ML. The virology and developments toward control of human enterovirus 71. *Crit Rev Microbiol*. 2011; 37:313–327.
32. Liang Z, Mao Q, Gao F and Wang J. Progress on the research and development of human enterovirus 71 (EV71) vaccines. *Front Med*. 2013; 7:111–121.
33. Shang L, Xu M and Yin Z. Antiviral drug discovery for the treatment of enterovirus 71 infections. *Antiviral Res*. 2013; 97:183–194.
34. Lao Y, Wan G, Liu Z, Wang X, Ruan P, Xu W, Xu D, Xie W, Zhang Y, Xu H and Xu N. The natural compound oblongifolin C inhibits autophagic flux and enhances anti-tumor efficacy of nutrient deprivation. *Autophagy*. 2014; 10:736–749.
35. Chen Y, Lin MC, Wang H, Chan CY, Jiang L, Ngai SM, Yu J, He ML, Shaw PC, Yew DT, Sung JJ and Kung HF. Proteomic analysis of EZH2 downstream target proteins in hepatocellular carcinoma. *Proteomics*. 2007; 7:3097–3104.
36. Deng L, Jia HL, Liu CW, Xu YF, Mao LJ, He CH, Yin GQ, Lin JH, Tao JP and Zhu L. Proteomic analysis of extremely severe hand, foot and mouth disease infected by enterovirus 71. *BMC Infect Dis*. 2013; 13:383.
37. Hansson SF, Korsgren S, Ponten F and Korsgren O. Enteroviruses and the pathogenesis of type 1 diabetes revisited: cross-reactivity of enterovirus capsid protein (VP1) antibodies with human mitochondrial proteins. *J Pathol*. 2013; 229:719–728.
38. Li G, Zhang XA, Wang H, Wang X, Meng CL, Chan CY, Yew DT, Tsang KS, Li K, Tsai SN, Ngai SM, Han ZC, Lin MC, He ML and Kung HF. Comparative proteomic analysis of mesenchymal stem cells derived from human bone marrow, umbilical cord and placenta: implication in the migration. *Adv Exp Med Biol*. 2011; 720:51–68.
39. Su PY, Wang YF, Huang SW, Lo YC, Wang YH, Wu SR, Shieh DB, Chen SH, Wang JR, Lai MD and Chang CF. Cell surface nucleolin facilitates enterovirus 71 binding and infection. *J Virol*. 2015; 89:4527–4538.
40. Wang RY, Kuo RL, Ma WC, Huang HI, Yu JS, Yen SM, Huang CR and Shih SR. Heat shock protein-90- $\beta$  facilitates enterovirus 71 viral particles assembly. *Virology*. 2013; 443:236–247.
41. Wang X, Chen Y, Han QB, Chan CY, Wang H, Liu Z, Cheng CH, Yew DT, Lin MC, He ML, Xu HX, Sung JJ and Kung HF. Proteomic identification of molecular targets of gambogic acid: role of stathmin in hepatocellular carcinoma. *Proteomics*. 2009; 9:242–253.
42. Zhang LK, Lin T, Zhu SL, Xianyu LZ and Lu SY. Global quantitative proteomic analysis of human glioma cells profiled host protein expression in response to enterovirus type 71 infection. *Proteomics*. 2015; 15:3784–3796.
43. Coe H, Jung J, Groenendyk J, Prins D and Michalak M. ERp57 modulates STAT3 signaling from the lumen of the endoplasmic reticulum. *J Biol Chem*. 2010; 285:6725–6738.
44. Lu J, Yi L, Zhao J, Yu J, Chen Y, Lin MC, Kung HF and He ML. Enterovirus 71 disrupts interferon signaling by reducing the level of interferon receptor 1. *Journal of virology*. 2012; 86:3767–3776.
45. Yi L, He Y, Chen Y, Kung HF and He ML. Potent inhibition of human enterovirus 71 replication by type I interferon subtypes. *Antivir Ther*. 2011; 16:51–58.
46. Lu J, Zhao FP, Peng Z, Zhang MW, Lin SX, Liang BJ, Zhang B, Liu X, Wang L, Li G, Tian WD, Peng Y, He ML and Li XP. EZH2 promotes angiogenesis through inhibition of miR-1/Endothelin-1 axis in nasopharyngeal carcinoma. *Oncotarget*. 2014; 5:11319–11332. doi: 10.18632/oncotarget.2435.
47. Lu J, He ML, Wang L, Chen Y, Liu X, Dong Q, Chen YC, Peng Y, Yao KT, Kung HF and Li XP. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. *Cancer Res*. 2011; 71:225–233.
48. Lu J, Xu X, Liu X, Peng Y, Zhang B, Wang L, Luo H, Peng X, Li G, Tian W, He M and Li X. Predictive value of miR-9 as a potential biomarker for nasopharyngeal carcinoma metastasis. *Br J Cancer*. 2014; 110:392–398.
49. Ma Y, Yu J, Chan HL, Chen YC, Wang H, Chen Y, Chan CY, Go MY, Tsai SN, Ngai SM, To KF, Tong JH, He QY, Sung JJ, Kung HF, Cheng CH, et al. Glucose-regulated protein 78 is an intracellular antiviral factor against hepatitis B virus. *Mol Cell Proteomics*. 2009; 8:2582–2594.